STOCK TITAN
  1. Home
  2. Sec-filings
  3. HURA
  4. [Form 4] TuHURA Biosciences, Inc./NV Insider Trading Activity

Form 4: Tendler Craig reports acquisition/exercise transactions in HURA

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tendler Craig reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.

Positive

  • None.

Negative

  • None.
Insider Tendler Craig
Role Director
Type Security Shares Price Value
Grant/Award Options (Right to Buy) 156,240 $0.00 --
holding Options (Right to Buy) -- -- --
Holdings After Transaction: Options (Right to Buy) — 156,240 shares (Direct)
Footnotes (1)
  1. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan previously granted on March 10, 2025. One-third of the stock options become exercisable on the first, second, and third anniversaries of March 10, 2025.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tendler Craig
(Last) (First) (Middle)
10500 UNIVERSITY CENTER DRIVE, SUITE 110
(Street)
TAMPA 33612
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
TuHURA Biosciences, Inc./NV [ HURA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Options (Right to Buy) $1.29 02/12/2026(1) A 156,240 (1) 02/12/2036 Common Stock 156,240 $0 156,240 D
Options (Right to Buy) $1.88 (2) 03/10/2035 Common Stock 151,883 151,883 D
Explanation of Responses:
1. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.
2. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan previously granted on March 10, 2025. One-third of the stock options become exercisable on the first, second, and third anniversaries of March 10, 2025.
/s/ Dan Dearborn as Power of Attorney for Craig Tendler 02/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did TuHURA Biosciences (HURA) director Craig Tendler report?

Craig Tendler reported receiving an annual grant of 156,240 stock options to buy TuHURA Biosciences common stock at an exercise price of $1.29 per share. The options were granted on February 12, 2026 under the company’s 2024 Equity Incentive Plan.

What are the vesting terms of Craig Tendler’s new TuHURA Biosciences (HURA) option grant?

The 156,240 stock options granted to Craig Tendler vest in three equal parts. One-third becomes exercisable on each of the first, second, and third anniversaries of February 12, 2026, as specified under the TuHURA Biosciences 2024 Equity Incentive Plan.

What additional stock options does Craig Tendler hold in TuHURA Biosciences (HURA)?

In addition to the new grant, Craig Tendler directly holds 151,883 stock options with a $1.88 exercise price, previously granted on March 10, 2025. These options vest in three equal annual installments starting on the first anniversary of March 10, 2025.

What is the exercise price and expiration date of Craig Tendler’s new TuHURA (HURA) options?

The new annual grant to Craig Tendler consists of 156,240 options with an exercise price of $1.29 per share, expiring on February 12, 2036. These options relate to TuHURA Biosciences common stock under the 2024 Equity Incentive Plan.

When do Craig Tendler’s previously granted TuHURA Biosciences (HURA) options expire?

Craig Tendler’s earlier award of 151,883 stock options, with a $1.88 exercise price, expires on March 10, 2035. They were granted on March 10, 2025 and vest in three equal tranches on the first, second, and third anniversaries of that grant date.

Is Craig Tendler’s ownership in TuHURA Biosciences (HURA) reported as direct or indirect?

The filing reports Craig Tendler’s holdings as direct ownership. Both the new grant of 156,240 stock options and the previously granted 151,883 stock options are listed as directly owned, with no indirect ownership entity described in the disclosure.